Search - tctmd.com

Displaying 401 - 420 of 455

Sort: Relevancy | Date

News Industry News

FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor

July 11, 2016

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2016

Shelley Wood

July 01, 2016

News Daily News

Media Scrutiny Over Risks and Benefits of Statins Impacts Patient Use

Michael O'Riordan

June 28, 2016

News Daily News

新分析质疑低密度脂蛋白胆固醇“越低越好”的说法，但专家仍呼吁应注意

Todd Neale

June 22, 2016

News Daily News

Un Nuevo Análisis Cuestiona el Mantra ‘Mejor Menos’, aunque los Expertos Piden Cautela

Todd Neale

June 22, 2016

News Daily News

‘Lower Is Better’ Mantra for LDL Cholesterol Questioned by New Analysis, but Experts Urge Caution

Todd Neale

June 22, 2016

News Daily News

Los Niveles de CRP Puede Identificar Riesgos CV Bajos en Pacientes Obesos Metabólicamente ‘Sanos’

L.A. McKeown

June 13, 2016

News Daily News

CRP 可以用于识别代谢“健康”的肥胖患者的低心血管风险

L.A. McKeown

June 13, 2016

News Daily News

CRP Can Identify Low CV Risk in Metabolically ‘Healthy’ Obese Patients

L.A. McKeown

June 13, 2016

News Daily News

Broader, Primary Prevention Role for High-Sensitivity Troponin Tests Suggested by ARIC Analysis

Shelley Wood

June 10, 2016

News Conference News EAS 2016

Non-HDL Cholesterol, Inflammation Appear to Be Linked in Patients Undergoing Elective PCI

Yael L. Maxwell

June 08, 2016

News Conference News EAS 2016

Preservation of LDL Cholesterol Targets for Lipid Lowering in New European Guidance Gets Blessing of Prevention Experts

Yael L. Maxwell

June 06, 2016

News Daily News

No More Niacin, Fibrate Combinations With Statins: FDA

Michael O'Riordan

April 19, 2016

News Conference News ACC 2016

Hints of What’s to Come in New Coronary Revascularization AUC

Caitlin E. Cox

April 12, 2016

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Conference News ACC 2016

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Michael O'Riordan

April 02, 2016

News Daily News

ACC 更新降低低密度脂蛋白胆固醇降低的建议，为依折麦布和 PCSK9 抑制剂留出了空间

Michael O'Riordan

April 02, 2016

News Daily News

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Michael O'Riordan

April 02, 2016

News Daily News

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

Michael O'Riordan

April 02, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol

February 04, 2016

Advertisement

FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor

TCTMD’s Top 10 Most Popular Stories for June 2016

Media Scrutiny Over Risks and Benefits of Statins Impacts Patient Use

新分析质疑低密度脂蛋白胆固醇“越低越好”的说法，但专家仍呼吁应注意

Un Nuevo Análisis Cuestiona el Mantra ‘Mejor Menos’, aunque los Expertos Piden Cautela

‘Lower Is Better’ Mantra for LDL Cholesterol Questioned by New Analysis, but Experts Urge Caution

Los Niveles de CRP Puede Identificar Riesgos CV Bajos en Pacientes Obesos Metabólicamente ‘Sanos’

CRP 可以用于识别代谢“健康”的肥胖患者的低心血管风险

CRP Can Identify Low CV Risk in Metabolically ‘Healthy’ Obese Patients

Broader, Primary Prevention Role for High-Sensitivity Troponin Tests Suggested by ARIC Analysis

Non-HDL Cholesterol, Inflammation Appear to Be Linked in Patients Undergoing Elective PCI

Preservation of LDL Cholesterol Targets for Lipid Lowering in New European Guidance Gets Blessing of Prevention Experts

No More Niacin, Fibrate Combinations With Statins: FDA

Hints of What’s to Come in New Coronary Revascularization AUC

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

ACC 更新降低低密度脂蛋白胆固醇降低的建议，为依折麦布和 PCSK9 抑制剂留出了空间

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content